Sames Lab Publishes Research to Hopefully Help Treat Psychiatric Disorders
Published in Nature in collaboration with researchers from Icahn School of Medicine at Mt. Sinai, these groundbreaking findings shed light on the potential therapeutic benefits of psychedelics, opening new doors for the development of medications for neuropsychiatric disorders.
Columbia Chemistry’s Dr. David Lankri, in collaboration with researchers from Icahn School of Medicine at Mt. Sinai, has identified a potent variant of the psychedelic 5-MeO-DMT.
This modified compound shows promising antidepressant-like effects in mice without the hallucinogenic properties of the original substance.
Be sure to read the full article below on Columbia News, and see more from the Sames Group below:
https://news.columbia.edu/news/could-toads-psychedelic-venom-help-treat-psychiatric-disorders